

Allergy Therapeutics^{PLC}

Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")

Results of General Meeting and Posting of Annual Report 2025

29 December 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that at the General Meeting held today, all resolutions were duly passed.

Results of General Meeting

All resolutions at the General Meeting were voted on by way of a poll. The results of the poll were as follows:

Resolution	For	%	Against	%	Total Cast	Votes	Withheld
Ordinary Resolution							
1. To authorise the directors to allot shares and to grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of £610,000.00	5,813,451,109	99.98	903,088	0.02	5,814,354,197		1,210
Special Resolution							
2. To disapply pre-emption rights in respect of an allotment of equity securities for cash pursuant to the authority granted by Resolution 1	5,810,471,464	99.93	3,882,733	0.07	5,814,354,197		1,210

The General Meeting was held as the Board is considering potentially undertaking an equity raise which would be structured by issuing New Shares to new investors and/or existing shareholders in the Company for cash consideration in one or more private placements on a non-pre-emptive basis (the "Potential Equity Raise").

In order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the Board sought and, at the General Meeting, obtained, shareholder approval for the allotment and issue of up to 610,000,000 ordinary shares of £0.001 each ("New Shares") (which is approximately 10% of the Company's current issued share capital) on terms that the Board may determine. In order for the Directors to issue New Shares free of statutory pre-emption rights, such statutory pre-emption rights must be dis-applied. Accordingly, the Board sought, and, at the General Meeting, obtained, shareholder approval to dis-apply pre-emption rights in respect of the allotment of the New Shares pursuant to the Potential Equity Raise.

At this time, there is no certainty that the Potential Equity Raise will proceed and at this point no investors have entered into any agreements to subscribe for New Shares and the amounts and price of any Potential Equity Raise have not been agreed. To the extent that any money is raised from the Potential Equity Raise, it would be applied towards the Company's stated strategy of developing treatments for grass and peanut allergy patients, and general corporate purposes, including the Company's working capital needs prior to its anticipated dual listing on the Hong Kong Stock Exchange.

The Directors shall have discretion to determine the terms of the Potential Equity Raise, including the number of New Shares to be issued (subject to the limits of the authorities) and the price at which the New Shares will be issued, as well as the identity of who the New Shares will be issued to. Further details of the Potential Equity Raise (if it proceeds) will be announced in due course.

Posting of Annual Report

The Company also announces that it has posted to shareholders the Annual Report and Accounts for the year ended 30 June 2025. The Annual Report and Accounts are available to download from the Company's website at www.allergytherapeutics.com.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMBXBDDUGDDGUC

[CLOSE THIS WINDOW](#)